Sutro Biopharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sutro Biopharma, Inc. (Nasdaq: STRO) on January 8, 2020, covering events that occurred on January 7, 2020. The Company is a Delaware corporation focused on biopharmaceutical development.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and director compensation.
Material Changes
On January 7, 2020, the Board of Directors appointed James Panek as a Class II director and member of the Science and Technology Committee, effective immediately.
Compensation and Governance Details
- Director Retainer: Mr. Panek will receive a pro rata portion of the $40,000 annual director retainer and a pro rata portion of the $5,000 annual Science and Technology Committee retainer for the remainder of the year.
- Stock Option Grant: The Board granted Mr. Panek an option to purchase 24,000 shares of common stock. The exercise price is equal to the closing sale price on January 7, 2020.
- Vesting Schedule: The stock option vests monthly over three years, contingent upon continued service.
- Indemnification: The Company entered into its standard form of indemnification agreement with Mr. Panek.
Outlook, Risks, and Contingencies
The filing text does not provide a clear value for guidance, outlook, management commentary on business risks, or unusual items. No family relationships or undisclosed material interests involving Mr. Panek were reported.
Key Facts for Investor Verification
- Confirmation of James Panek's appointment as a Class II director and Science and Technology Committee member.
- Verification of the 24,000 share stock option grant and its specific vesting terms.
- Confirmation that the exercise price for the option matches the Nasdaq closing price on January 7, 2020.
- Review of the standard indemnification agreement filed previously as Exhibit 10.1 to the Form S-1.